Syncor posts healthy 1998 numbers
Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997’s $1.7 million. Net sales for the quarter increased 25% to $119 million, up
Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997s $1.7 million. Net sales for the quarter increased 25% to $119 million, up from $94.8 million. The Woodland Hills, CA, company enjoyed net sales for the year of $449 million, up 18% from $380.6 million in 1997, and net income of $13.9 million, compared with $11.1 million the year before.
Syncor attributed its healthy results to its first price increase in six years, as well as its effort to control costs, which improved its gross margins. The company increased its operating income for its radiopharmacy business in 1998 to $21.4 million, up 64% from $13 million in 1997. In addition, Syncors imaging center subsidiary, Comprehensive Medical Imaging, contributed $37.5 million in sales to the company in fiscal 1998.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
